NRG-RTOG 0848 Closure Notice

RTOG 0848, “A Phase II-R and a Phase III Trial Evaluating Both *Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma,” will close to accrual at 5 PM ET Friday, June 1, 2018, because it has reached its accrual target.  Step 2 randomization will remain open.  All patients registered to Step 1 by Friday, June 1, 2018 will proceed to the randomization step (Step 2).  If patients are unable to be randomized, Step 2 will still be completed with the reason for no randomization being provided.

Reminder: Data collection and site IRB renewal for closed studies must continue until the study is terminated.

Please distribute this information to the appropriate personnel at participating affiliate/NCORP component institutions.

*(Ph II-R Erlotinib Randomization Completed, Arm 2 Closed to Accrual Effective 04/02/14)

View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.
Twitter
This message was sent from NRG-Broadcasts@NRGOncology.org to NRG-Broadcasts@NRGOncology.org
Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address | Forward Email | Report Abuse